MedTrace Logo

Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy

NCT01845688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-04-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

Losartan Tablets & QingReMoShen Granule

DRUG

Losartan Tablets & Placebo Granule

Sponsors & Collaborators

  • wanglin

    lead OTHER

Principal Investigators

  • Lin Wang, PHD,MD · Shanghai University of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-02-29
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01845688 on ClinicalTrials.gov